Indaptus Therapeutics Inc INDP

$2.38 +0.26 (12.26%)

Valuation

Market cap
282,473,000
Revenue TTM
$0
Net income TTM
$-20,850,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
568,100
Avg volume
1,028,864
Day's range
$1.94 – $2.42
Shares out
133,242,000
Stochastic %K
19%
Beta
0.96
Analysts
Strong Buy
Price target
$10.00

Price

Company profile

Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency...

Show more

Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.

Industry
Biotechnology
Sector
Healthcare
Phone
646 427 2727
Website
https://indaptusrx.com
Address
Three Columbus Circle, 15th Floor, New York, United States

Latest news